BioStem Technologies, Inc. Common Stock (BSEM) is a publicly traded the market company. As of November 12, 2026, BSEM trades at $1.06 with a market cap of $27.45M and a P/E ratio of 0.00. BSEM moved -12.24% today. Year to date, BSEM is -67.30%; over the trailing twelve months it is -72.32%. Its 52-week range spans $1.00 to $15.74. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces BSEM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioStem raises 2026 revenue guidance and plans $10 million-$12 million in cost cuts: BioStem Technologies reported third-quarter revenue of $7.64 million and a net loss of $11.4 million, or $0.64 per share, and raised its 2026 revenue guidance to $28 million-$29 million. It is finalizing a cost reduction plan expected to lower annualized cash operating expenses by $10 million-$12 million, with the full benefit expected in the first quarter of 2027.
| Metric | Value |
|---|---|
| Price | $1.06 |
| Market Cap | $27.45M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.74 |
| 52-Week Low | $1.00 |
| Volume | 366.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover BSEM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.